Catalysts for Elrexfio
8 tracked
Apr 27, 2026
phase 3 completion
CellCarta Biosciences Inc — elranatamab (Phase III Trial Completion)
elranatamab
→
Mar 25, 2026
approval
ELREXFIO (ELRANATAMAB) — FDA approval
elranatamab
→
Feb 19, 2026
approval
ELREXFIO (ELRANATAMAB) — FDA approval
elranatamab
→
Jul 10, 2025
approval
ELREXFIO (ELRANATAMAB) — FDA approval
elranatamab
→
Jul 8, 2025
approval
ELREXFIO (ELRANATAMAB) — FDA approval
elranatamab
→
Sep 10, 2024
approval
ELREXFIO (ELRANATAMAB) — FDA approval
elranatamab
→
Dec 13, 2023
approval
ELREXFIO (ELRANATAMAB) — FDA approval
elranatamab
→
Aug 14, 2023
approval
ELREXFIO (ELRANATAMAB) — FDA approval
elranatamab
→